Development of cutaneous amelanotic melanoma in the absence of a functional tyrosinase

Pigment Cell Research

Volumn 14, Issue 6, 2001, Pages 466-474

  Cohen Solal, Karine A ^a   Reuhl, Kenneth R ^a   Ryan, Kevin B ^a   Roberts, Kathleen G ^a   Chen, Suzie ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Melanocyte; Melanocyte specific markers; Premelanosomes; Transgenic mouse model; Tumorigenesis

Indexed keywords

ANIMALIA; MUS MUSCULUS;

DOPACHROME OXIDOREDUCTASE; ISOMERASE; MONOPHENOL MONOOXYGENASE; PROTEIN; TYROSINASE RELATED PROTEIN; TYROSINASE-RELATED PROTEIN;

AMELANOTIC MELANOMA; ANIMAL; ARTICLE; DISEASE MODEL; ENZYMOLOGY; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; MALE; MELANOCYTE; MELANOSOME; METABOLISM; MOUSE; MOUSE STRAIN; MUTATION; NUTRITIONAL DEFICIENCY; PATHOLOGY; PHENOTYPE; SKIN; TRANSGENIC MOUSE; ULTRASTRUCTURE; UPREGULATION;

ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MELANOCYTES; MELANOMA, AMELANOTIC; MELANOMA, EXPERIMENTAL; MELANOSOMES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MONOPHENOL MONOOXYGENASE; MUTATION; PHENOTYPE; PROTEINS; SKIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; UP-REGULATION;

EID: 0035542879     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0749.2001.140607.x     Document Type: Article

References (38)

1. Amelanotic malignant melanoma
2. Cytodiagnosis of amelanotic metastatic malignant melanoma: An immunocytochemical study
3. Dermatopathologic variants of malignant melanoma
4. Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene
5. Transgenic mouse model for skin malignant melanoma
6. Malignant melanoma in transgenic mice
7. Melanocyte culture lines from Tyr-SV40E transgenic mice: Models for the molecular genetic evolution of malignant melanoma
8. Histopathogenesis of malignant skin melanoma induced in genetically susceptible transgenic mice
9. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
10. Essential role for oncogenic Ras in tumour maintenance
11. Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene
12. Induction of melanoma in TPras transgenic mice
13. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor
14. Spontaneous melanocytosis in transgenic mice
15. Development of heritable melanoma in transgenic mice
16. Development of early melanocytic lesions in transgenic mice predisposed to melanoma
17. A point mutation in the tyrosinase gene of BALB/c albino mouse causing the cysteine → serine substitution at position 85
18. Conserved cysteine to serine mutation in tyrosinase is responsible for the classical albino mutation in laboratory mice
19. Antigen retrieval immunohistochemistry: Past, present and future
20. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase
21. Biochemical control of melanogenesis and melanosomal organization
22. Regulation of tyrosinase in human melanocytes grown in culture
23. Tyrosinases of murine melanocytes with mutation at the albino locus
24. S-100 protein remains a practical marker for melanocytic and other turmours
25. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes
26. Immunohistochemistry in the diagnosis of melanocytic neoplasms
27. S-100 protein-negative malignant melanoma: Fact or fiction?
28. Analysis of Pmell7/gp100 expression in primary human tissue specimens: Implications for melanoma immuno- and gene-therapy
29. A sensitive and specific melanocyte marker for melanoma diagnosis
30. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype
31. Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: Utilization in design of syngeneic immunotherapy models
32. Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: A projected basis for immunotherapy
33. Mutations at critical N-glycosylation sites reduce tyrosinase activity by altering folding and quality control
34. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells
35. Sorting and secretion of a melanosome membrane protein, gp75/TRP1
36. Malignant melanoma in a patient with oculocutaneous albinism